Renalytix LinkedIn Contact Us
Renalytix Investors

Holding(s) in Company

published · source · RNS
all News Releases

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:Renalytix PLC GB00BYWL4Y04
1b. Please indicate if the issuer is a non-UK issuer  (please mark with an “X” if appropriate)


2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rightsX
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify) iii: UBS trading book holdings in Renalytix PLC fell below 5% and are therefore exempt from reporting.X
3. Details of person subject to the notification obligation iv
NameUBS Group AG – Investment Bank & Global Wealth Management
City and country of registered office (if applicable)Zürich Switzerland
4. Full name of shareholder(s) (if different from 3.) v
Name
City and country of registered office (if applicable)
5. Date on which the threshold was crossed or reached vi:10 September 2025
6. Date on which issuer notified (DD/MM/YYYY):11 September 2025
7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)% of voting rights through financial instruments
(total of 8.B 1 + 8.B 2)
Total of both in % (8.A + 8.B)Total number of voting rights held in issuer (8.A + 8.B) vii
Resulting situation on the date on which threshold was crossed or reached0.000000%0.000000%0.000000%0
Position of previous notification (if applicable)5.046243%0.000000%5.046243%
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii
A: Voting rights attached to shares
Class/type of
shares
ISIN code (if possible)
Number of voting rights ix% of voting rights
Direct (DTR5.1)Indirect  (DTR5.2.1)Direct (DTR5.1)Indirect (DTR5.2.1)
GB00BYWL4Y04
0
0.000000%










SUBTOTAL 8. A00.000000%
   
B 1: Financial Instruments according to DTR5.3.1R (1) (a)
Type of financial instrumentExpiration
date
x
Exercise/
Conversion Period
xi
Number of voting rights that may be acquired if the instrument is exercised/converted.% of voting rights

















SUBTOTAL 8. B 1

   
B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)
Type of financial instrumentExpiration
date
x
Exercise/
Conversion Period
xi
Physical or cash Settlement xiiNumber of voting rights% of voting rights




















 SUBTOTAL 8.B.2

   
9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii
Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv
X
Name xv% of voting rights if it equals or is higher than the notifiable threshold% of voting rights through financial instruments if it equals or is higher than the notifiable thresholdTotal of both if it equals or is higher than the notifiable threshold
UBS Group AG


UBS AG


 
10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held

11. Additional information xvi
  UBS trading book holdings in Renalytix PLC fell below 5% and are therefore exempt from reporting.
Place of completionZurich, Switzerland
Date of completion11.09.2025